SUN Financial News

Subscribe to enjoy similar stories.Asset management companies (AMCs) largely held up their full-year earnings performance in FY26, but mark-to-market losses stemming from the West Asia conflict dented their latest quarterly profit. Listed AMCs recorded a sequential decrease in net profit or a loss in the January-March quarter.ICICI Prudential AMC reported a 16.8% quarter-on-quarter (QoQ) decline in net profit to ₹763 crore in Q4.

Subscribe to enjoy similar stories.Aditya Birla Sun Life Asset Management Co. is raising a ₹2,000 crore alternative investment fund (AIF) that will target the stocks of mid- and small-cap companies, joining a growing list of asset managers targeting wealthy investors with hedge fund-style products.The fund, ABSL Select Sector Fund, will open with a base corpus of ₹1,500 crore and a greenshoe option of ₹500 crore, executives at the Mumbai-based firm said.

Subscribe to enjoy similar stories.Mumbai: When Dilip Shanghvi walked into the press conference to announce Sun Pharmaceutical’s acquisition of Organon & Co.—an $11.75 billion deal that will effectively double the company’s revenue to $12.4 billion—he offered a rare admission.“I’m happy, excited, also a little bit anxious,” he told journalists, adding that the sheer size of the transaction reminded him of announcing the Ranbaxy Laboratories deal a decade ago.Back then, Sun was a fraction of its current size. This time, it is acquiring a company roughly equal in size, paying for it with cash and borrowed money rather than stock, and doing so at what Shanghvi described as “less than 25% of Sun’s own value.”At the surface, the Organon deal is a story about scale—a large Indian generics company buying an even larger portfolio of established branded drugs and biosimilars from a spun-off Merck subsidiary.

Subscribe to enjoy similar stories.Sun Pharmaceutical Industries Ltd’s acquisition of Organon might yet avoid the pitfalls that its rivals, Lupin Ltd and Biocon Ltd, have faced in the past. Billed as among the largest deals in the Indian pharma space, the Sun-Organon deal is in a better place than the Lupin-Gavis and the Biocon-Viatris deals.When Lupin completed the acquisition of US-based Gavis Pharmaceuticals in March 2016, the former’s stock went downhill.

Subscribe to enjoy similar stories.Sun Pharma would appear to have got itself a sweet deal when it agreed to acquire all outstanding shares of US-based Organon for $3.7 billion in cash at $14 per share.The US pharma company had outstanding debt of $8.6 billion at the end of 2025, annual sales of $6.2 billion and adjusted Ebitda of $1.9 billion (i.e., earnings before interest, taxes, depreciation and amortization). Its enterprise value of $11.75 billion, as widely reported, is the sum of its stock value and debt, less cash on hand.

Subscribe to enjoy similar stories.Mumbai: India’s second-biggest overseas acquisition was stitched together over three months of near-daily negotiations between the bidder, the seller and their bankers, said a banker aware of the details behind the transaction.Mumbai-based Sun Pharmaceutical Industries Ltd on Monday said in an exchange filing it will acquire US-headquartered Organon & Co for about $11.75 billion. This is the largest overseas deal by an Indian company since Tata Steel acquired UK-based Corus Group for $12 billion in 2007.The deal was always pitched at around $12 billion from both sides, with negotiations neither exceeding nor materially falling from that level, the person cited above said on the condition of anonymity.“The deal was out in the market sometime late 2025, and Sun was very interested because it gave them access to more than 100 countries across the world and also complemented the product suite,” said the banker.

Subscribe to enjoy similar stories.Sun Pharmaceutical Industries Ltd on Monday announced the $11.75 billion acquisition of Organon & Co., in a seemingly aggressive push into the US market that has long decided the global fortunes of Indian drugmakers. However, the biggest buyout by an Indian company in nearly 20 years also signals that the US generics market's decades-long allure is beginning to fade for Indian drugmakers, which are now eyeing newer markets such as China, South Korea, and Spain with branded generics.Announced early on Monday, the Organon acquisition ranks as the second-largest acquisition by an Indian company, behind Tata Steel's 2007 deal to buy British steel maker Corus Group for $12 billion.For years, Indian pharma rode a powerful wave in the US, as expiring patents of blockbuster small-molecule drugs opened a gold mine for low-cost generic drug makers in the world's largest drug market.

Subscribe to enjoy similar stories.Mumbai: From technology to automobiles to pharmaceuticals, Indian companies are scaling up their global ambitions like never before.They are using large acquisitions overseas to quickly scale, deliver higher value products and compete on the global stage. The latest one—Sun Pharmaceutical Industries Ltd’s $11.75 billion acquisition of US-based specialty drugmaker Organon & Co, second only to the Tata Steel's $12-billion purchase of Corus Group nearly two decades ago, caps a year of such bold bets.Whether it is Coforge Ltd’s $2.39 billion buyout of California-based Encora, Tata Motors Ltd’s $4.5 billion bet on Italy’s Iveco, or Bajaj Auto Ltd’s $906 million acquisition of its long-time Austrian partner KTM, Indian companies are spending top dollar on acquiring companies overseas, which give them access to technology and newer markets.Coforge is an IT services provider that caters to legacy companies.

Subscribe to enjoy similar stories.With its $11.75 billion acquisition of Organon, a Merck spinoff, Sun Pharmaceutical has officially embarked on one of the most ambitious overseas expansions ever by an Indian pharmaceutical company. Markets cheered the announcement on 27 April, sending the stock soaring almost 7%.This reflects optimism around scale expansion and strategic repositioning.

Subscribe to enjoy similar stories.Japan has decided to ease restrictions on its sale of weapons to other countries, although this would be limited to the 17 with which it has defence tie-ups. As India is part of the four-nation Quad—with Japan, the US and Australia as other members—Tokyo’s move opens up a possibility worth close consideration by New Delhi. We could diversify our set of high-tech arms suppliers to include a non-hegemonic power with which we have had good relations for eight decades.

Novo Nordisk to treat type-2 diabetes, semaglutide, delivered in an injection, has gained global attention for its weight-loss benefits. The drug is sold under brand names Ozempic, Wegovy and Rybelsus (oral pill) by the Danish pharma giant.With patent protection expiring, companies including Dr.

Sun Pharma, said that the industry has been taking tentative steps towards innovation. “People are making investments to create capacity within their organization to manage innovation, so that at a certain point of time, we can become an equally important player globally in terms of innovative products,” he said.“But I still don't see innovation at scale…We are very tentative in terms of that investment,” he said.

Subscribe to enjoy similar stories. The volatility in the stock market can be your best friend. The swinging markets offer a plethora of great long-term opportunities.

Subscribe to enjoy similar stories. NEW DELHI : India’s technology outsourcing services are likely to “die out" over the next five years, as artificial intelligence automates most software programming and quality engineering tasks, according to Vinod Khosla, founder of Khosla Ventures and early-stage investor in OpenAI—the world’s most valuable AI startup.

Subscribe to enjoy similar stories. Things are never dull in the Musk-onomy. Take Monday.

Subscribe to enjoy similar stories. The budget is unlikely to cause a meaningful shift in the assessment of equities from a medium-term perspective, and so investors should look at markets through a fresh lens to identify which newer themes could emerge as winners, said Harish Krishnan, chief investment officer - Equity at Aditya Birla Sun Life AMC Ltd. After the budget classified tax on buybacks as capital gains, some relief for buybacks may help return excess capital in a few mature companies, which can then be recycled into newer capital-intensive opportunities, said Krishnan.

Subscribe to enjoy similar stories. The Indian stock market witnessed a sharp fall in intraday trade on Sunday, after the finance minister presented her ninth consecutive budget. The Sensex closed 1,546.84 points lower at 80,722.94, while the Nifty shed 495.20 points to settle at 24,825.45, reflecting a decline of nearly 2%.

Subscribe to enjoy similar stories. Sun Pharma, India’s largest drugmaker, is set to post its results for the third quarter of the fiscal year on Saturday. While brokerages anticipate steady domestic growth and marginal sequential growth in its US business, driven by its innovative drugs, margins may contract due to increased spending.

Subscribe to enjoy similar stories. India’s largest drugmaker Sun Pharma is reportedly bidding for American pharmaceutical company Organon in a deal that could potentially be worth $10 billion, which would make it the largest overseas acquisition by an Indian pharma company. The drugmaker has secured $10–14 billion in temporary ‘bridge loans’ to fund the move.

Subscribe to enjoy similar stories. As India’s pharmaceutical sector kicks off its earnings season for the quarter ended December on Friday, analysts expect muted margins. A key reason for this is the loss of patent exclusivity for the blood cancer drug Revlimid in the US.

Mint reported on 23 December, quoting official data, that Japan is now the fifth-largest source of foreign direct investment into India.MUFG, which is one of Japan’s largest private lenders, is in discussions with multiple Indian IT services firms, including Tech Mahindra, for hiring support, the two people said, though the bank’s current India headcount could not be independently verified.The lender has two tech centres in Bengaluru to support back-end IT functions for the bank and enterprise solutions for the parent firm. MUFG ended last fiscal year with a net interest income of $20.8 billion, up 12% from the year-ago period.“They are mainly having talent requirements for Linux, .NET, and Java roles, apart from other AI and cybersecurity requirements,” said one of the two people.Manufacturing conglomerates are making similar moves.